BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Leukemia AND BCL2, Bcl-2, 596, ENSG00000171791
7149 results:

  • 1. (2,6-Dimethylphenyl)arsonic Acid Induces Apoptosis through the Mitochondrial Pathway, Downregulates XIAP, and Overcomes Multidrug Resistance to Cytostatic Drugs in leukemia and Lymphoma Cells In Vitro.
    Wilke N; Frias C; Berkessel A; Prokop A
    Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731935
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Decreased apoptotic priming and loss of bcl-2 dependence are functional hallmarks of Richter's syndrome.
    Rigo A; Vaisitti T; Laudanna C; Terrabuio E; Micillo M; Frusteri C; D'Ulivo B; Merigo F; Sbarbati A; Mellert K; Möeller P; Montresor A; Di Napoli A; Cirombella R; Butturini E; Massaia M; Constantin G; Vinante F; Deaglio S; Ferrarini I
    Cell Death Dis; 2024 May; 15(5):323. PubMed ID: 38724507
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. A phase 3b study of venetoclax and azacitidine or decitabine in an outpatient setting in patients with acute myeloid leukemia.
    Manda S; Anz BM; Benton C; Broun ER; Yimer HA; Renshaw JS; Geils G; Berdeja J; Cruz J; Melear JM; Fanning S; Fletcher L; Li Y; Duan Y; Werner ME; Potluri J; Pai MV; Donnellan WB
    Hematol Oncol; 2024 May; 42(3):e3274. PubMed ID: 38711253
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. [Study on the inhibitory and pro-apoptotic effects of different concentrations of total tanshinone alone and in combination with tyrosine kinase inhibitors on human myeloid leukemia cell lines].
    Zhou XS; Fang JC; Ma XL; Zhang Y; Wang F; Chen X; Wu QS; Cao PX; Liu HX
    Zhonghua Yi Xue Za Zhi; 2024 May; 104(17):1514-1520. PubMed ID: 38706059
    [No Abstract]    [Full Text] [Related]  

  • 5. Assessment of the
    Nasr GM; Thawabieh OM; Talaat RM; Moawad M; El Hamshary MO
    Front Biosci (Landmark Ed); 2024 Apr; 29(4):162. PubMed ID: 38682177
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Improved Survival of Patients With Chronic Lymphocytic leukemia Between 1998-2022, Including the Era of Target Therapies With bcl2 and BTK Inhibitors.
    Tadmor T; Melamed G; Alapi H; Gazit S; Patalon T; Rokach L
    Anticancer Res; 2024 May; 44(5):2109-2115. PubMed ID: 38677726
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Putting the STING back into BH3-mimetic drugs for TP53-mutant blood cancers.
    Diepstraten ST; Yuan Y; La Marca JE; Young S; Chang C; Whelan L; Ross AM; Fischer KC; Pomilio G; Morris R; Georgiou A; Litalien V; Brown FC; Roberts AW; Strasser A; Wei AH; Kelly GL
    Cancer Cell; 2024 May; 42(5):850-868.e9. PubMed ID: 38670091
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. [Research Progress of Targeted Therapy for Chronic Lymphocytic leukemia/Small Lymphocytic Lymphoma --Review].
    Chen D; Wang MY; Tian C
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Apr; 32(2):643-646. PubMed ID: 38660880
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. [Effect of Shikonin on Autophagy and Apoptosis of Human Promyelocytic leukemia Cells].
    Chen Y; Xie XM; Zhang XL; Zhang XL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Apr; 32(2):416-421. PubMed ID: 38660845
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. [Reversal Effect of Arctigenin on the Drug Resistance in leukemia K562/A02 Cells and Its Mechanism].
    Zou L; Fang Y; He W
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Apr; 32(2):409-415. PubMed ID: 38660844
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. MNDA expression and its value in differential diagnosis of B-cell non-Hodgkin lymphomas: a comprehensive analysis of a large series of 1293 cases.
    Zhang LF; Zhang Y; Shui RH; Lu HF; Jiang WH; Cai X; Li XQ; Yu BH
    Diagn Pathol; 2024 Apr; 19(1):60. PubMed ID: 38627702
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Identification of a novel form of caspase-independent cell death triggered by BH3-mimetics in diffuse large B-cell lymphoma cell lines.
    Yildirim N; Sarojam L; Smith VM; Pieper NM; Anders M; Jackson RA; Fuhrmann DC; Särchen V; Brücher D; Weigert A; Dyer MJS; Vogler M
    Cell Death Dis; 2024 Apr; 15(4):266. PubMed ID: 38622118
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Design, Synthesis, and Anti-Leukemic Evaluation of a Series of Dianilinopyrimidines by Regulating the Ras/Raf/MEK/ERK and STAT3/c-Myc Pathways.
    Wang C; Wang B; Mou Y; Liu X; Chen Q; Pu W; Rao Q; Wang C; Song J; Huang Y; Yan L; Huang L; Li Y
    Molecules; 2024 Apr; 29(7):. PubMed ID: 38611876
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. A novel α,β-unsaturated ketone inhibits leukemia cell growth as PARP1 inhibitor.
    Zhao W; Mo M; Yu J; Cheng S; Long G; Luo Z; Liang W; Yan C; Luo H; Sun B
    Med Oncol; 2024 Apr; 41(5):113. PubMed ID: 38602586
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Targeting Myeloid leukemia-1 in Cancer Therapy: Advances and Directions.
    Deng H; Han Y; Liu L; Zhang H; Liu D; Wen J; Huang M; Zhao L
    J Med Chem; 2024 Apr; 67(8):5963-5998. PubMed ID: 38597264
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Single-cell systems pharmacology identifies development-driven drug response and combination therapy in B cell acute lymphoblastic leukemia.
    Huang X; Li Y; Zhang J; Yan L; Zhao H; Ding L; Bhatara S; Yang X; Yoshimura S; Yang W; Karol SE; Inaba H; Mullighan C; Litzow M; Zhu X; Zhang Y; Stock W; Jain N; Jabbour E; Kornblau SM; Konopleva M; Pui CH; Paietta E; Evans W; Yu J; Yang JJ
    Cancer Cell; 2024 Apr; 42(4):552-567.e6. PubMed ID: 38593781
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Discovery of novel co-degradation CK1α and CDK7/9 PROTACs with p53 activation for treating acute myeloid leukemia.
    Wang K; Jiang M; Liu H; Meng C; Li M; Lu H
    Bioorg Chem; 2024 Jun; 147():107319. PubMed ID: 38593529
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Honokiol induces apoptosis and autophagy in dexamethasone-resistant T-acute lymphoblastic leukemia CEM-C1 cells.
    Liu Y; Zhang S; Tan Y
    Hematology; 2024 Dec; 29(1):2337307. PubMed ID: 38573223
    [No Abstract]    [Full Text] [Related]  

  • 19. [Safety and efficacy of 7-day administration of azacitidine and venetoclax combination therapy (7+7 therapy)].
    Osada Y; Kanai-Sudo H; Mizuki T; Tanosaki S; Suzuki K
    Rinsho Ketsueki; 2024; 65(3):135-141. PubMed ID: 38569855
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. [Study of a patient with Myelodysplastic/myeloproliferative neoplasm with co-morbid neutrophilia and a novel NCOR1::GLYR1 fusion gene].
    Lei Y; Zhao X; Zhao H; Cheng Y; Wang S; Li J; Zhu Y
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2024 Apr; 41(4):404-410. PubMed ID: 38565504
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 358.